BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Platt HL, Greenberg D, Tapiero B, Clifford RA, Klein NP, Hurley DC, Shekar T, Li J, Hurtado K, Su SC, Nolan KM, Acosta CJ, McFetridge RD, Bickham K, Musey LK; V114-008 Study Group. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatr Infect Dis J 2020;39:763-70. [PMID: 32639460 DOI: 10.1097/INF.0000000000002765] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Banniettis N, Wysocki J, Szenborn L, Phongsamart W, Pitisuttithum P, Rämet M, Richmond P, Shi Y, Dagan R, Good L, Papa M, Lupinacci R, McFetridge R, Tamms G, Churchill C, Musey L, Bickham K; V114-024 PNEU-PLAN study group. A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN). Vaccine 2022:S0264-410X(22)01086-6. [PMID: 36150974 DOI: 10.1016/j.vaccine.2022.09.003] [Reference Citation Analysis]
2 Hu T, Song Y, Done N, Liu Q, Sarpong EM, Lemus-Wirtz E, Signorovitch J, Mohanty S, Weiss T. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018. BMC Public Health 2022;22:1677. [PMID: 36064378 DOI: 10.1186/s12889-022-14051-6] [Reference Citation Analysis]
3 Ryman J, Weaver J, Yee KL, Sachs JR. Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children. Expert Rev Vaccines 2022;:1-7. [PMID: 35997125 DOI: 10.1080/14760584.2022.2112179] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hu T, Podmore B, Barnett R, Beier D, Galetzka W, Qizilbash N, Haeckl D, Weaver J, Boellinger T, Mihm S, Petigara T. Incidence of acute otitis media in children < 16 years old in Germany during 2014-2019. BMC Pediatr 2022;22:204. [PMID: 35418046 DOI: 10.1186/s12887-022-03270-w] [Reference Citation Analysis]
5 Hu T, Done N, Petigara T, Mohanty S, Song Y, Liu Q, Lemus-wirtz E, Signorovitch J, Sarpong E, Weiss T. Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07275-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Downs SL, Madhi SA, Van der Merwe L, Nunes MC, Olwagen CP. High-throughput nanofluidic real-time PCR to discriminate Pneumococcal Conjugate Vaccine (PCV)-associated serogroups 6, 18, and 22 to serotypes using modified oligonucleotides. Sci Rep 2021;11:23728. [PMID: 34887480 DOI: 10.1038/s41598-021-03127-9] [Reference Citation Analysis]
7 Morelli L, Lay L, Santana-Mederos D, Valdes-Balbin Y, Verez Bencomo V, van Diepen A, Hokke CH, Chiodo F, Compostella F. Glycan Array Evaluation of Synthetic Epitopes between the Capsular Polysaccharides from Streptococcus pneumoniae 19F and 19A. ACS Chem Biol 2021;16:1671-9. [PMID: 34469105 DOI: 10.1021/acschembio.1c00347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Koufoglou E, Kourlaba G, Michos A. Effect of prophylactic administration of antipyretics on the immune response to pneumococcal conjugate vaccines in children: a systematic review. Pneumonia (Nathan) 2021;13:7. [PMID: 33894782 DOI: 10.1186/s41479-021-00085-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Principi N, Esposito S. Pneumococcal Disease Prevention: Are We on the Right Track? Vaccines (Basel) 2021;9:305. [PMID: 33804822 DOI: 10.3390/vaccines9040305] [Cited by in F6Publishing: 2] [Reference Citation Analysis]